Literature DB >> 15947240

Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study.

Claudia Imke1, Beatriz L Rodriguez, John S Grove, Judith R McNamara, Carol Waslien, Alan R Katz, Bradley Willcox, Katsuhiko Yano, J David Curb.   

Abstract

BACKGROUND: Remnant-like particles have been proposed as a new risk factor for coronary heart disease (CHD). This is the first long-term prospective investigation of the relationship between remnant-like particles and a cardiovascular disease outcome in healthy men. METHODS AND
RESULTS: A cohort of 1156 Japanese-American men aged 60 to 82 from the Honolulu Heart Program was followed for 17 years. During that period 164 incident cases of CHD were identified. In multivariate Cox regression analyses, baseline remnant-like particle cholesterol (RLP-C) and triglyceride (RLP-TG) levels were significantly related to CHD incidence independently of nonlipid cardiovascular risk factors and of total cholesterol or high-density and low-density lipoprotein cholesterol levels. Total triglyceride levels were an independent predictor of CHD incidence. However, in models including RLP and triglyceride level simultaneously, neither variable was significant when adjusted for the other. This finding can be attributed to the strong correlation between RLP-C and RLP-TG levels and total triglycerides. When individuals with normal triglyceride levels (n=894) were separated from those with elevated triglycerides (n=260), the association between RLPs and CHD relative risk was only significant for the group with elevated triglyceride levels.
CONCLUSIONS: RLP levels predicted CHD incidence independently of nonlipid risk factors and of total cholesterol or high-density and low-density lipoprotein cholesterol levels. However, RLP levels did not provide additional information about CHD incidence over and above total triglyceride levels. Therefore, this study does not support the need for testing of remnants in men if measures of fasting triglycerides are available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947240     DOI: 10.1161/01.ATV.0000173310.85845.7b

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  19 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Authors:  Jixin Zhong; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Clin Lipidol       Date:  2015

Review 3.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

4.  Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.

Authors:  Ye-Xuan Cao; Hui-Wen Zhang; Jing-Lu Jin; Hui-Hui Liu; Yan Zhang; Rui-Xia Xu; Ying Gao; Yuan-Lin Guo; Cheng-Gang Zhu; Qi Hua; Yan-Fang Li; Raul D Santos; Na-Qiong Wu; Jian-Jun Li
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

5.  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.

Authors:  Vasilios G Athyros; Anna I Kakafika; Athanasios A Papageorgiou; Konstantinos Tziomalos; Athanasios Skaperdas; Efstathios Pagourelias; Athina Pirpasopoulou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lipids       Date:  2007-08-23       Impact factor: 1.880

Review 6.  The role of triglycerides in cardiovascular risk.

Authors:  Puneet Gandotra; Michael Miller
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

7.  Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids.

Authors:  Peter P Toth; Thomas D Dayspring; Gregory S Pokrywka
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

8.  The correlation between TG vs remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Hyun Duk Moon; Takeaki Nagamine; Kimber L Stanhope; Peter J Havel; G Russell Warnick
Journal:  Clin Chim Acta       Date:  2009-04-01       Impact factor: 3.786

9.  Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life.

Authors:  John A Morrison; Charles J Glueck; Paul S Horn; Samrat Yeramaneni; Ping Wang
Journal:  Metabolism       Date:  2009-06-18       Impact factor: 8.694

Review 10.  A Fishy Topic: VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting Omega-3 Fatty Acids into Practice in 2021.

Authors:  Tahreem Iqbal; Michael Miller
Journal:  Curr Cardiol Rep       Date:  2021-07-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.